Why the study?
How does the Sabin strain of type 3 poliovirus evolve antigenically and molecularly during excretion by a primary vaccinee?
How does the Sabin strain of type 3 poliovirus evolve antigenically and molecularly during excretion by a primary vaccinee?
The Sabin type 3 poliovirus vaccine strain undergoes rapid molecular evolution through recombination and point mutations during excretion in a primary vaccinee, while maintaining main immunodominant antigenic site stability.
Answers are grounded in this paper and cite their sources.
Extended excretion of recombinant poliovirus strains may warrant surveillance vigilance; single case leaves open transmission risks.
A 4 month old child was immunized with a vaccine containing the Sabin live attenuated vaccine strains of all three serotypes of poliovirus. The antigenic and molecular evolution of the Sabin strain of poliovirus type 3 was then followed throughout the entire period of virus excretion. Novel strains appeared at 8, 42 and 52 days post-vaccination and were the products of both intertypic recombination between type 2 and type 3 poliovirus in regions of the genome coding for non-structural proteins and of point mutations in the region coding for the structural proteins. Excretion of virus continued for 73 days. All strains examined reacted with all monoclonal antibodies specific for the main immunodominant antigenic site of type 3 poliovirus, but variation was observed at other, immunorecessive sites. These findings have possible implications for the evolution of the virus in vaccinees or in epidemics and are consistent with the known antigenic stability of the virus.
No takes yet. Share an insight, caveat, or question.
Minor et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: